Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda

To screen for drug resistance and possible treatment with Dolutegravir (DTG) in treatment-naive patients and those experiencing virologic failure during first-, second-, and third-line combined antiretroviral therapy (cART) in Uganda. Samples from 417 patients in Uganda were analyzed for predicted d...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:AIDS Res Hum Retroviruses
Autores principales: Ndashimye, Emmanuel, Avino, Mariano, Kyeyune, Fred, Nankya, Immaculate, Gibson, Richard M., Nabulime, Eva, Poon, Art F.Y., Kityo, Cissy, Mugyenyi, Peter, Quiñones-Mateu, Miguel E., Arts, Eric J.
Formato: Artigo
Lenguaje:Inglês
Publicado: Mary Ann Liebert, Inc. 2018
Materias:
Epidemiology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5934975/
https://ncbi.nlm.nih.gov/pubmed/29353487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/aid.2017.0205
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares